{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:43:41Z","timestamp":1793861021623,"version":"4.6.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms. We quantified its incremental efficacy and safety against semaglutide 2.4 mg monotherapy in adults with overweight or obesity, with and without type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This PRISMA 2020\u2013compliant review (PROSPERO CRD420261380458) searched PubMed, Embase, Cochrane CENTRAL, ScienceDirect, ClinicalTrials.gov and WHO ICTRP to 30 June 2026 for randomised controlled trials comparing CagriSema with semaglutide 2.4 mg or placebo. Effects were pooled within two prespecified comparator strata using random-effects models with restricted maximum likelihood estimation of \u03c4\u00b2 and a Hartung\u2013Knapp\u2013Sidik\u2013Jonkman small-sample adjustment, with prediction intervals, leave-one-out and phase-3a-restricted sensitivity analyses, trial sequential analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five trials (4,746 unique participants) were included. Versus semaglutide 2.4\u00a0mg, CagriSema produced greater weight loss (mean difference \u22126.89 percentage points, 95% CI \u22128.70 to \u22125.06; I\u00b2 = 33%; prediction interval \u22128.91 to \u22124.86), a greater absolute reduction in body weight (\u22127.16 kg, 95% CI \u22129.15 to \u22125.17) and in body-mass index (\u22122.41 kg\/m\u00b2, 95% CI \u22122.83 to \u22121.99), and roughly twice the likelihood of reaching a 20% reduction (RR 2.10, 95% CI 1.78 to 2.47). Waist circumference fell further (\u22124.07 cm, 95% CI \u22125.10 to \u22123.04). No incremental glycaemic benefit was detected, with intervals for glycated haemoglobin (\u22120.07, 95% CI \u22120.14 to 0.01) and fasting plasma glucose lying entirely within prespecified minimal important differences. Injection-site reactions were more frequent (RR 3.14, 95% CI 1.42 to 6.96); gastrointestinal adverse events were not significantly increased under the primary model (RR 1.09, 95% CI 0.97 to 1.21).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events. The evidence is insufficient to determine whether serious adverse events or neoplasms differ between treatments, and long-term durability, cardiovascular outcomes and body composition remain undetermined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261380458.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1903335","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:54:05Z","timestamp":1790945645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zehra Khatoon","family":"Rasool","sequence":"first","affiliation":[{"name":"DePaul University","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi","family":"Shah","sequence":"additional","affiliation":[{"name":"Narendra Modi Medical College","place":["Ahmedabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansharah E Zinnia","family":"Batool","sequence":"additional","affiliation":[{"name":"Rashid Latif Medical College","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutvi","family":"Shah","sequence":"additional","affiliation":[{"name":"Narendra Modi Medical College","place":["Ahmedabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Khachatryan","sequence":"additional","affiliation":[{"name":"Fanarjyan Clinic","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Kathmandu University School of Medical Sciences","place":["Dhulikhel, Nepal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ali","sequence":"additional","affiliation":[{"name":"Services Institute of Medical Sciences","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeran","family":"Atta","sequence":"additional","affiliation":[{"name":"Services Institute of Medical Sciences","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pugazhandhi","family":"Bakthavatchalam","sequence":"additional","affiliation":[{"name":"American University of Antigua","place":["St. John's, Antigua and Barbuda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Muhammad Hadeed","family":"Khawar","sequence":"additional","affiliation":[{"name":"Services Institute of Medical Sciences","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb","family":"Khawar","sequence":"additional","affiliation":[{"name":"King Edward Medical University","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","volume-title":"World Obesity Atlas 2025","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin - its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet (London England)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00402-4","article-title":"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial","volume":"14","author":"Yamauchi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_45_24","article-title":"Efficacy and safety of cagrilintide alone and in combination with semaglutide (Cagrisema) as anti-obesity medications: a systematic review and meta-analysis","volume":"28","author":"Dutta","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70667","article-title":"Efficacy and safety of cagrilintide and cagrisema versus semaglutide as anti-obesity medications: a systematic review, meta-analysis and meta-regression","volume":"28","author":"Ahmed","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.amjcard.2026.02.030","article-title":"CagriSema versus semaglutide monotherapy or placebo for obesity: a systematic review and meta-analysis of randomised controlled trials with GRADE assessment","volume":"267","author":"Gadelmawla","year":"2026","journal-title":"Am J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-00733-x","article-title":"Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data","volume":"45","author":"Wharton","year":"2021","journal-title":"Int J Obes (2005)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J Educ Behav Stat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clin Trials"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4097\/kja.20637","article-title":"Trial sequential analysis: plain and simple","volume":"74","author":"De Cassai","year":"2021","journal-title":"Korean J Anesthesiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial sequential analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2022.0043.R1.07042022","article-title":"Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study","volume":"140","author":"Bezerra","year":"2022","journal-title":"Sao Paulo Med J = Rev Paulista Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet (London England)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076","article-title":"Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review","volume":"7","author":"Bays","year":"2023","journal-title":"Obes Pillars"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-372161","article-title":"Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis","volume":"394","author":"Nong","year":"2026","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1903335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:54:06Z","timestamp":1790945646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1903335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1903335"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1903335","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1903335"}}